List Labs is proud to be exhibiting at the Microbiome Drug Develoment Summit 2018 in Boston, MA. The conference will be held at the Boston Seaport World Trade Center from June 20-22. This conference provides access to the latest preclinical, clinical and commercial case studies from the brightest minds in biopharma and academia to turn microbiome discoveries into patient therapies.
Contact us to schedule a meeting with us at the show to discuss your next project!
By: Rachel Berlin, Marketing Manager
Linda Shoer, Founder of List Labs, exhibiting at ASM in the 90’s
List Labs is proud to be exhibiting at the ASM Microbe Conference again this year. The meeting will be held June 7-11th in Atlanta, GA at the Georgia World Congress Center. List Labs has been exhibiting at this conference for over 20 years and is excited to be back in 2018. ASM Microbe showcases the best microbial sciences in the world and provides a forum to explore the complete spectrum of microbiology from basic science to translation and application.
List Labs has extensive experience with microbiome and more specifically live biotherapeutic projects including vaginal, gut, skin and the central nervous system indication and tumor treatment – many of which have completed Phase I and Phase II trials. Stop by our booth and find out how we can help you with your next microbiome project. Learn about how scientists have used List Labs’ products for their microbiome research on our citations page.
Interested in scheduling a meeting with us during the conference? Contact us!
By: Nancy Shine, PhD, Director of R&D, List Labs
Nancy Shine presenting her poster at ASM Biothreats February, 2018
Bacillus anthracis is regarded as a major biological warfare threat. The inhalation form of Bacillus anthracis infection can kill quickly. While antibiotic treatment can clear the bacterium from the host, if diagnosis is delayed, the toxin, which is rapidly produced, may already be present in lethal amounts. There is a critical need for a rapid, accurate, sensitive and simple assay to determine whether infection has occurred thereby allowing immediate treatment.
Anthrax Detection Method
Anthrax lethal factor (LF), an endopeptidase, is present in blood in the early stages of the infection. The use of peptidic substrates in plasma is problematic due to the presence of other proteases and the likelihood of nonspecific cleavage of the substrate. A fluorescently labeled peptide substrate, MAPKKide Plus, Prod #532, which is not cleaved by plasma proteases and thus is specific for LF has been designed. The LF is enriched by capture from plasma using an LF antibody-coated microtiter plate, and the captured LF is then exposed to the fluorescent substrate. The amount of cleaved peptide substrate is determined by HPLC with fluorescence detection. Concentration of the LF using the antibody-coated plates allows for the detection of 5 pg LF/ml of neat plasma after 2 hours of incubation. Alternately, the MAPKKide Plus may be added directly to diluted plasma and cleavage monitored by an increase in fluorescence as a function of time using a fluorescent microplate reader. The limit of detection by this simpler method is 1 ng LF/ml of plasma after 5 hours of digestion. Both methods can be confirmed by analysis of the reaction as a function of time. These methods are described in the poster Sensitive Detection of Anthrax Lethal Factor in Plasma Using a Specific Biotinylated Fluorogenic Substrate.
What’s Next for Anthrax Detection Method
We are currently working with a biotinylated form of MAPKKide Plus to enhance the sensitivity of the simpler method using the fluorescent plate reader rather than HPLC.
You can see the poster here. To see a complete list of all of List Labs’ posters check out this blog post.
Interested in learning more about this List Labs patented peptide substrate? Contact us!
By: Rachel Berlin, Marketing Manager
List Labs is proud to be exhibiting at ASM Biothreats February 12-14th. The conference will be held in Baltimore, Maryland at the Hilton Hotel.
Thought leaders in academia, industry and government will gather to present and discuss the latest developments in the emerging field of biothreats. This year’s conference has an expanded program to include tracks on high consequence pathogen research, biological threat reduction, product development, and policy.
List Labs will be exhibiting in booth #29 and Nancy Shine will be presenting her poster on Sensitive Detection of Anthrax Lethal Factor in Plasma Using a Specific Biotinylated Fluorogenic Substrate during poster session 1 on Wednesday, February 14th from 10:30 AM- 11:30 AM in space #020. Come learn about our products that assist in the biological threat reduction such Botulinum Neurotoxins, Anthrax Lethal Factor,FRET Peptides, Shiga Toxins, Tetanus Toxins, and more! All of our research reagents are available for purchase on our website.
Visit Nancy and Karen in the List Labs booth #29, or contact us to schedule a time to meet with them at the show. Click here for more information or to register for this conference.
By: Shawn Lyles, Marketing Manager
List Labs will be attending the 54th annual Interagency Botulism Research Coordinating Committee (IBRCC) this year from October 27-30th. The conference will be held in Ellicott City, MA at the Turf Valley Resort and Conference Center. This international forum presents state-of-the-art research on botulinum toxin and the deadly disease of botulism. This important conference provides the opportunity for federal and non-federal agencies to coordinate in the effort against botulism in all of it’s forms.
The following List Labs employees will be attending the conference:
List Labs currently has nearly 50 botulinumrelated products including recombinant light chain, heavy chain, antibodies and specific substrates in stock. See how scientists have used List Labs’ reagents in their research projects on our citations page.